Lifesci Capital Reiterates Outperform Rating for Perspective Therapeutics (NYSEAMERICAN:CATX)

Perspective Therapeutics (NYSEAMERICAN:CATX)‘s stock had its “outperform” rating reiterated by Lifesci Capital in a report issued on Monday, Zacks.com reports. Lifesci Capital also issued estimates for Perspective Therapeutics’ FY2024 earnings at ($0.12) EPS and FY2025 earnings at ($0.14) EPS.

CATX has been the subject of several other reports. B. Riley boosted their target price on shares of Perspective Therapeutics from $1.20 to $1.70 and gave the company a “buy” rating in a research note on Tuesday, April 9th. Oppenheimer reiterated an “outperform” rating and issued a $1.50 price objective (up previously from $1.20) on shares of Perspective Therapeutics in a research report on Monday, April 1st.

Perspective Therapeutics Stock Down 4.3 %

CATX stock opened at 1.76 on Monday. The company has a current ratio of 1.07, a quick ratio of 1.07 and a debt-to-equity ratio of 0.02. Perspective Therapeutics has a 12 month low of 0.21 and a 12 month high of 1.90. The firm has a market capitalization of $1.03 billion, a PE ratio of -17.60 and a beta of 1.43.

Insiders Place Their Bets

In related news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the firm’s stock in a transaction that occurred on Wednesday, March 6th. The stock was purchased at an average cost of 0.95 per share, for a total transaction of 57,409,487.05. Following the completion of the acquisition, the insider now owns 116,773,394 shares in the company, valued at approximately 110,934,724.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 3.52% of the company’s stock.

Hedge Funds Weigh In On Perspective Therapeutics

Large investors have recently bought and sold shares of the business. Perkins Capital Management Inc. acquired a new stake in Perspective Therapeutics during the third quarter worth approximately $731,000. HighTower Advisors LLC purchased a new stake in Perspective Therapeutics in the third quarter valued at $314,000. Taylor & Morgan Wealth Management LLC boosted its stake in Perspective Therapeutics by 8.7% in the fourth quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company’s stock valued at $251,000 after acquiring an additional 50,000 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in shares of Perspective Therapeutics during the third quarter worth about $42,000. Finally, Bleakley Financial Group LLC acquired a new stake in shares of Perspective Therapeutics during the first quarter worth about $40,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.